Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function

Condition:   Type2Diabetes Intervention:   Drug: PB119 Sponsor:   PegBio Co., Ltd. Not yet recruiting

Source: ClinicalTrials.gov - April 14, 2022 Category: Research Source Type: clinical trials